logo-loader

Zelda enters rapidly-growing German market with product commercialisation strategy

Last updated: 20:46 09 Sep 2018 EDT, First published: 06:46 09 Sep 2018 EDT

Zelda Therapeutics Ltd (ASX:ZLD) founder and executive chairman Harry Karelis updates Proactive Investors on the cannabis company’s progress with clinical trials as well as its recent entry into the German market.
 
Zelda has entered a distribution and manufacturing strategic partnership with German medicinal cannabis group HAPA Medical.
 
As per the deal, HAPA will have first rights to distribute and/or manufacture Zelda’s clinically validated formulations into the rapidly growing German market.
 
With a population of 83 million people, Germany is estimated to have the potential to become the world’s largest single medical cannabis market.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

13 minutes ago